[HbA.sub.1c] will be the test for most.
If you put all of that into clinical practice, many primary care physicians find that the ability to measure [HbA.sub.lc] at any time of the day, and to combine it with assessment of other cardiovascular risk factors, makes pragmatic sense. That's where the practice is going.
We need more evidence on whether using [HbA.sub.lc] and fasting glucose together improves our ability to predict risk of microvascular complications. We are forgetting that we can repeat tests over time as people progress with their disease. Each factor will progress.
[HbA.sub.lc] is more expensive than fasting glucose, so the cost-benefit ratio must be determined. If we start to introduce wide-scale [HbA.sub.lc] testing, how much extra cost will there be to detect more patients with diabetes? The difference is probably $l-$2 per test per patient. It's a cost that we probably would be willing to make. And it's more convenient for patients.
I think [HbA.sub.lc] will become the preferred test for diabetes in the vast majority of individuals, although there is a subgroup of people in whom glucose measures will still be used.
NAVEED SATTAR, M.D., is professor of metabolic medicine at the University of Glasgow, Scotland. He said he has no relevant conflicts of interest.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||VIEW ON THE NEWS|
|Publication:||Internal Medicine News|
|Date:||Jul 1, 2011|
|Previous Article:||Two tests better than one to peg prediabetes.|
|Next Article:||Liraglutide curbs glycemic oscillations in type 1 diabetes.|